I tenim una revisió sistemàtica @cochranecollab del 2017, amb 14 ACR i 867 pacients inclosos, que conclou que el flumazenil no redueix la mortalitat, però sí que pot millorar la gravetat de l’EH, almenys transitòriament, amb un RR 0,75 (0,71 a 0,80). http
@fernandbteich @AdamRodmanMD @sargsyanz @tony_breu @DxRxEdu @drmerando @medrants I have used flumazenil for this but the evidence isn’t too strong. https://t.co/8zq3pHfP9n
#Flumazenil in hepatic encephalopathy: no effect on mortality (as reasonably expected), but maybe a short-term beneficial effect on encephalophaty (low-evidence data).a clue to keep in mind in comatose flumazenil-responsive pts? @FedeRebustello @vetrone88
Open Access UCL Research: Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy https://t.co/DwT7fZMcmp
Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic… https://t.co/oRmtJBhx2c